Cargando…

Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies

INTRODUCTION: This study investigated factors associated with the antihypertensive effects of esaxerenone and the incidence of serum potassium elevation in patients with hypertension. METHODS: Using pooled data from seven phase III studies, the study analyzed factors associated with changes in offic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Sadayoshi, Okuda, Yasuyuki, Sugimoto, Kotaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988784/ https://www.ncbi.nlm.nih.gov/pubmed/36662393 http://dx.doi.org/10.1007/s12325-022-02393-x

Ejemplares similares

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies
por: Shikata, Kenichi, et al.
Publicado: (2022)

Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2020)

Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2019)

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
por: Ito, Sadayoshi, et al.
Publicado: (2021)

Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes
por: Kario, Kazuomi, et al.
Publicado: (2021)

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
por: Ito, Sadayoshi, et al.
Publicado: (2019)

Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect
por: Ichikawa, Shuichi, et al.
Publicado: (2022)

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism
por: Fujimoto, Masanori, et al.
Publicado: (2023)

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial
por: Okuda, Yasuyuki, et al.
Publicado: (2022)

Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
por: Itoh, Hiroshi, et al.
Publicado: (2019)

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
por: Satoh, Fumitoshi, et al.
Publicado: (2020)

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020)

Association of Antihypertensive Effects of Esaxerenone with the Internal Sodium Balance in Dahl Salt-Sensitive Hypertensive Rats
por: Hattori, Mai, et al.
Publicado: (2022)

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males
por: Toyama, Kaoru, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study
por: Uchida, Haruhito A., et al.
Publicado: (2022)

Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study
por: Kario, Kazuomi, et al.
Publicado: (2023)

Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker
por: Arai, Kiyoshi, et al.
Publicado: (2020)

Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE‐HT study
por: Kario, Kazuomi, et al.
Publicado: (2023)

Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH)
por: Motoki, Hirohiko, et al.
Publicado: (2023)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity
por: Okamura, Keisuke, et al.
Publicado: (2020)

Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study　― Protocol for a Multicenter, Open-Label, Exploratory Interventional Study ―
por: Sueta, Daisuke, et al.
Publicado: (2022)

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled( )
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Seven‐Membered Cyclic Potassium Diamidoalumanyls
por: Schwamm, Ryan J., et al.
Publicado: (2021)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

A Case of a Pregnant Woman With Primary Aldosteronism and Superimposed Preeclampsia Treated With Esaxerenone
por: Yamashita, Kaoru, et al.
Publicado: (2022)

Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
Publicado: (2022)

Feasibility and antihypertensive effect of replacing regular salt with mineral salt -rich in magnesium and potassium- in subjects with mildly elevated blood pressure
por: Sarkkinen, Essi S, et al.
Publicado: (2011)

Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats
por: Rahman, Asadur, et al.
Publicado: (2021)

Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
por: Chang, Wei-Ting, et al.
Publicado: (2021)

ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance
por: Kuwabara, Saki, et al.
Publicado: (2022)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study
por: Iwahana, Togo, et al.
Publicado: (2021)

Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy: A Pooled Cohort Analysis
por: Parcha, Vibhu, et al.
Publicado: (2021)

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2021)

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents
por: Lengel, Dave, et al.
Publicado: (2015)

Antihypertensive effects of astaxanthin
por: Yanai, Hidekatsu, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_opk26oasq6ps17rkvshjkgn4fn